$17.76
3.35% today
Nasdaq, Apr 03, 07:12 pm CET
ISIN
US1717571079
Symbol
CDTX
Sector
Industry

Cidara Therapeutics, Inc. Stock price

$18.37
-4.68 20.30% 1M
+7.82 74.12% 6M
-8.51 31.66% YTD
-3.03 14.16% 1Y
+0.17 0.93% 3Y
-29.43 61.57% 5Y
-301.63 94.26% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.55 2.91%
ISIN
US1717571079
Symbol
CDTX
Sector
Industry

Key metrics

Market capitalization $201.22m
Enterprise Value $8.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.98
P/S ratio (TTM) P/S ratio 22.94
P/B ratio (TTM) P/B ratio 1.23
Revenue growth (TTM) Revenue growth -86.28%
Revenue (TTM) Revenue $8.77m
EBIT (operating result TTM) EBIT $-93.37m
Free Cash Flow (TTM) Free Cash Flow $-176.66m
Cash position $196.18m
EPS (TTM) EPS $-29.69
P/E forward negative
Short interest 2.81%
Show more

Is Cidara Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Cidara Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cidara Therapeutics, Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Cidara Therapeutics, Inc. forecast:

Buy
100%

Financial data from Cidara Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
8.77 8.77
86% 86%
100%
- Direct Costs 1.74 1.74
31% 31%
20%
7.03 7.03
89% 89%
80%
- Selling and Administrative Expenses 23 23
39% 39%
258%
- Research and Development Expense 78 78
13% 13%
884%
-93 -93
297% 297%
-1,062%
- Depreciation and Amortization 0.23 0.23
78% 78%
3%
EBIT (Operating Income) EBIT -93 -93
281% 281%
-1,065%
Net Profit -168 -168
612% 612%
-1,916%

In millions USD.

Don't miss a Thing! We will send you all news about Cidara Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cidara Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted Timothy Alefantis, a new employee, a non-qualified stock option a...
Neutral
GlobeNewsWire
2 days ago
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that company management will participate in the 24th Annual Needham Virtual Healthcare Conference. Details are as follows: Event: 24th Annual Needham Virtual Healthcare Confe...
Neutral
GlobeNewsWire
15 days ago
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the “Other pharmaceuticals as preventive tools” panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The me...
More Cidara Therapeutics, Inc. News

Company Profile

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Jeffrey Stein
Employees 38
Founded 2012
Website www.cidara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today